A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
- Conditions
- Seasonal Influenza
- Interventions
- Biological: mRNA-1010Biological: Licensed quadrivalent inactivated seasonal influenza vaccine
- Registration Number
- NCT05566639
- Lead Sponsor
- ModernaTX, Inc.
- Brief Summary
The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22502
-
Investigator has assessed that the participant understands and is willing and physically able to comply with protocol mandated follow-up, including all procedures.
- For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose on Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration.
- Participant has had close contact with someone with laboratory-confirmed influenza infection or with someone who has been treated with antiviral therapies for influenza (for example, Tamiflu®) within the past 5 days prior to the Screening visit.
- Participant has had close contact to someone with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or COVID-19 as defined by the US CDC or has had a positive SARS-CoV-2 test in the past 10 days prior to the Screening visit.
- Participant is acutely ill or febrile (temperature ≥38.0℃elcius [100.4°Fahrenheit]) 72 hours prior to or at the Screening visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window.
- Participant has a history of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
- Reported history of congenital or acquired immunodeficiency, immunocompromising/ immunosuppressive condition, asplenia, or recurrent severe infections.
- Reported history of anaphylaxis or severe hypersensitivity reaction after receipt of any mRNA or influenza vaccines or any components of the mRNA or influenza vaccines, including egg protein.
- Participant has received systemic immunosuppressant drugs for >14 days in total within 180 days prior to the Screening visit (for glucocorticosteroids, ≥10 milligrams (mg)/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study. Inhaled, nasal, and topical steroids are allowed.
- Participant has received any vaccine authorized or approved by local health agency ≤28 days prior to study intervention (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after the study intervention.
- Participant is unaware whether they have received an influenza vaccine in the previous influenza season.
- Participant received a seasonal influenza vaccine or any other investigational influenza vaccine within 180 days prior to Day 1
- Participant has tested positive for influenza by local health authority-approved testing methods within 180 days prior to Day 1.
- Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening visit or plans to donate blood products during the study.
Note: Other inclusion and exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description mRNA-1010 mRNA-1010 Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1. Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine Licensed quadrivalent inactivated seasonal influenza vaccine Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1. mRNA-1010 mRNA-1010 Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1. Fluarix Quadrivalent Fluarix Quadrivalent Participants will receive a single dose of Fluarix Quadrivalent by IM injection on Day 1.
- Primary Outcome Measures
Name Time Method Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) 7 days post-vaccination Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Number of Participants With Unsolicited Adverse Events (AEs) Up to 28 days post-vaccination An unsolicited AE was an AE that was not solicited using a participant diary and that was communicated by a participant who has signed the informed consent. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.
Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Discontinuation Day 1 through Day 361 (Month 12) An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 361) are reported in this outcome measure.
Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine 14 days post-vaccination through Day 181 (Month 6) Protocol-defined ILI: The presence of body temperature ≥37.5 degrees celsius (°C) (≥99.5 degrees fahrenheit \[°F\]), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive Reverse Transcription Polymerase Chain Reaction (RT-PCR) for influenza.
- Secondary Outcome Measures
Name Time Method Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined ILI Caused by Influenza A or B Strains With Similarity to Those Selected for the Seasonal Vaccine 14 days post-vaccination through Day 181 (Month 6) Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.
Number of Participants With First Episode of RT-PCR-Confirmed Protocol-Defined ILI Caused by Influenza A or B Strains Antigenically Matched to the Vaccine Strains Selected for the Seasonal Vaccine 14 days post-vaccination through Day 181 (Month 6) Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.
Number of Participants With First Episode of RT-PCR Confirmed United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains 14 days post-vaccination through Day 181 (Month 6) CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.
Number of Participants With First Episode of RT-PCR CDC-Defined ILI Caused by Influenza A or B Strains With Similarity to Vaccine Strains 14 days post-vaccination through Day 181 (Month 6) CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.
Number of Participants With First Episode of RT-PCR CDC-Defined ILI Caused by Influenza A or B Strains That Were Antigenically Matched to Vaccine Strains 14 days post-vaccination through Day 181 (Month 6) CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.
Number of Participants With First Episode of Culture-Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine 14 days post-vaccination through Day 181 (Month 6) Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.
Number of Participants With First Episode of Culture-Confirmed CDC-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine 14 days post-vaccination through Day 181 (Month 6) CDC-defined ILI: The presence of temperature ≥37.8°C \[≥100°F\], accompanied by at least one of the respiratory illness symptoms (cough and/or sore throat) and a positive RT-PCR for influenza.
Number of Participants With Hospitalizations Associated With RT-PCR Confirmed Protocol-Defined ILI Caused by Any Seasonal Influenza A or B Virus Strains Regardless of Antigenic Match to Strains Selected for the Seasonal Vaccine 14 days post-vaccination through Day 181 (Month 6) Protocol-defined ILI: The presence of body temperature ≥37.5°C (≥99.5°F), accompanied by at least one of the respiratory illness symptoms (sore throat, cough, sputum production, wheezing, or difficulty breathing) and a positive RT-PCR for influenza.
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B Strains Day 29 Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% confidence interval (CI) was calculated based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation.
Percentage of Participants Reaching Seroconversion at Day 29, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains Day 29 Seroconversion was defined as either a Baseline HAI titer \<1:10 and a post-Baseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in post-Baseline HAI antibody titer.
Percentage of Participants With HAI Titer ≥ 1:40 at Day 29 Day 29 Geometric Mean Fold Rise (GMFR) of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains Baseline, Day 29 The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% CI for GMFR was calculated based on the t distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Trial Locations
- Locations (221)
Velocity Clinical Research - Westlake
🇺🇸Los Angeles, California, United States
CCT Research
🇺🇸Las Vegas, Nevada, United States
South Florida Research Center, Inc.
🇺🇸Miami, Florida, United States
Suncoast Research Associates Trials, LLC
🇺🇸Miami, Florida, United States
Santa Rosa Medical Centers of Nevada/ CCT Research
🇺🇸Las Vegas, Nevada, United States
Acclaim Clinical Research
🇺🇸San Diego, California, United States
Sterling Research Group
🇺🇸Cincinnati, Ohio, United States
CTI Clinical Research Center
🇺🇸Cincinnati, Ohio, United States
Velocity Clinical Research - Cincinnati
🇺🇸Cincinnati, Ohio, United States
Clinical Trials of Texas, Inc
🇺🇸San Antonio, Texas, United States
Shawn K Hassler MD
🇺🇸San Francisco, California, United States
Las Vegas Clinical Trials, LLC
🇺🇸North Las Vegas, Nevada, United States
Montana Medical Research, Inc
🇺🇸Missoula, Montana, United States
SHAT of Pneumo-phthisiatric diseases - Sofia District
🇧🇬Sofia, Bulgaria
Medical Center Medconsult Pleven
🇧🇬Pleven, Bulgaria
Military Medical Academy
🇧🇬Sofia, Bulgaria
Taipei Medical University - Taipei Medical University Hospital
🇨🇳Taipei, Taiwan
MHAT Sveti Ivan Rilski
🇧🇬Kozloduy, Bulgaria
ETG Skierniewice
🇵🇱Skierniewice, Poland
MHAT "Dr. Stamen Iliev
🇧🇬Montana, Bulgaria
Centrum Innowacyjnych Terapii Sp. z o.o.
🇵🇱Warszawa, Poland
Tri-Service General Hospital - Neihu Branch - Infectious Diseases
🇨🇳Taipei, Taiwan
Velocity Clinical Research, Denver
🇺🇸Denver, Colorado, United States
Aviva Clinical Trials Group Inc
🇨🇦Burlington, Canada
KO-MED Centra Kliniczne Lublin II
🇵🇱Lublin, Poland
Provita Centrum Medyczne Sp. z o.o.
🇵🇱Warszawa, Poland
RCMed
🇵🇱Warszawa, Poland
Velocity Clinical Research - Syracuse
🇺🇸Syracuse, New York, United States
West Coast Research LLC
🇺🇸San Ramon, California, United States
Medical Center for Clinical Research
🇺🇸San Diego, California, United States
Arthritis & Rheumatology - Clinic of Northern Colorado
🇺🇸Fort Collins, Colorado, United States
Longmont Medical Research Network
🇺🇸Longmont, Colorado, United States
Homestead Associates in Research,Inc
🇺🇸Hialeah, Florida, United States
Broward Research Group
🇺🇸Hollywood, Florida, United States
Nature Coast Clinical Research, LLC - Crystal River
🇺🇸Crystal River, Florida, United States
Floridian Clinical Research
🇺🇸Hialeah, Florida, United States
Encore Research Group-Jacksonville Center for Clinical Resea
🇺🇸Jacksonville, Florida, United States
Health Awareness, Inc
🇺🇸Jupiter, Florida, United States
Accel Research Sites - Lakeland
🇺🇸Lakeland, Florida, United States
ARS - Meridien Research
🇺🇸Maitland, Florida, United States
Multi-Therapeutic Research Associates, Inc.
🇺🇸Lake City, Florida, United States
Global Health Research Center
🇺🇸Miami Lakes, Florida, United States
Clinical Trials of Florida, LLC
🇺🇸Miami, Florida, United States
New Tampa Health, Inc
🇺🇸Tampa, Florida, United States
Miami centre of clinical research
🇺🇸Miami, Florida, United States
Tekton Research, Inc.
🇺🇸Chamblee, Georgia, United States
Velocity Clinical Research - Boise
🇺🇸Meridian, Idaho, United States
iResearch Atlanta, LLC
🇺🇸Decatur, Georgia, United States
In-Quest Medical Research
🇺🇸Norcross, Georgia, United States
Mount Vernon Clinical Research
🇺🇸Sandy Springs, Georgia, United States
Velocity Clinical Research - Valparaiso
🇺🇸Valparaiso, Indiana, United States
Meridian Clinical Research - Savannah
🇺🇸Savannah, Georgia, United States
Chicago Health Medical Group
🇺🇸River Forest, Illinois, United States
Heartland Research Associates LLC
🇺🇸Newton, Kansas, United States
Johnson County Clin-Trials (JCCT)
🇺🇸Lenexa, Kansas, United States
Alliance for Multispecialty Research
🇺🇸Wichita, Kansas, United States
Privia Medical Group
🇺🇸Annapolis, Maryland, United States
Meridian Clinical Research
🇺🇸Portsmouth, Virginia, United States
MedPharmics
🇺🇸Covington, Louisiana, United States
Rockville Internal Medicine Group
🇺🇸Rockville, Maryland, United States
Delricht Research
🇺🇸Hendersonville, Tennessee, United States
DM Clinical Research - Detroit
🇺🇸Southfield, Michigan, United States
CCT Research at Skyline Medical Center, PC
🇺🇸Elkhorn, Nebraska, United States
National Medical University and Embryonic Tissues Center EmC
🇺🇸Springfield, Missouri, United States
Papillon Research Centre
🇺🇸Omaha, Nebraska, United States
Medpace, Inc. - Clinical Pharmacology Unit (CPU)
🇺🇸Norfolk, Nebraska, United States
CCT Research / Methodist Physicians Clinic, Prairie Fields Family Medicine, PC
🇺🇸Fremont, Nebraska, United States
Rochester Clinical Research, Inc
🇺🇸Rochester, New York, United States
Midwest Regional Health Services, LLC/CCT Research
🇺🇸Omaha, Nebraska, United States
Clinical Research Center of Nevada LLC
🇺🇸Las Vegas, Nevada, United States
Meridian Clinical Research - Omaha
🇺🇸Omaha, Nebraska, United States
Diabetes & Endocrinology Consultants
🇺🇸Morehead City, North Carolina, United States
M3 Wake Research, Inc.
🇺🇸Raleigh, North Carolina, United States
United Medical Associates
🇺🇸Binghamton, New York, United States
Platinum Research Network, LLC
🇺🇸Beaumont, Texas, United States
PMG Research of Wilmington
🇺🇸Wilmington, North Carolina, United States
Carolina Institute for Clinical Research
🇺🇸Fayetteville, North Carolina, United States
Delricht Research Tulsa
🇺🇸Tulsa, Oklahoma, United States
Lynn Health Science Institute
🇺🇸Oklahoma City, Oklahoma, United States
Velocity Clinical Research - Columbia
🇺🇸Columbia, South Carolina, United States
Trial Management Associates
🇺🇸Wilmington, North Carolina, United States
Tekton Research, Inc
🇺🇸Austin, Texas, United States
Carolina Health Specialists
🇺🇸Myrtle Beach, South Carolina, United States
Texas Center for Drug Development, Inc.
🇺🇸Houston, Texas, United States
Benchmark Research
🇺🇸Fort Worth, Texas, United States
DM Clinical Research
🇺🇸Sugar Land, Texas, United States
Spartanburg Regional Health Services
🇺🇸Spartanburg, South Carolina, United States
Black Hills Center for American Indian Health
🇺🇸Rapid City, South Dakota, United States
Olympus Family Medicine/CCT Research
🇺🇸Holladay, Utah, United States
DELRICHT RESEARCH at ZOMNIR FAMILY MEDICINE
🇺🇸McKinney, Texas, United States
Zenos Clinical Research
🇺🇸Dallas, Texas, United States
CenExel - JBR
🇺🇸Salt Lake City, Utah, United States
Cope Family Medicine
🇺🇸Bountiful, Utah, United States
Breco Research - A Tarheel Clinical Research Site
🇺🇸Sugar Land, Texas, United States
Research Your Health
🇺🇸Plano, Texas, United States
South Ogden Family Medicine clinic/CCT
🇺🇸South Ogden, Utah, United States
Lakeview Medical Center
🇺🇸Suffolk, Virginia, United States
MC City Clinic Sveti Georgi - Montana
🇧🇬Montana, Bulgaria
Aggarwal and Associates LTD
🇨🇦Brampton, Canada
LMC Manna
🇨🇦Pointe-Claire, Canada
Okanagan Clinical Trials
🇨🇦Kelowna, Canada
Centricity Research Quebec City
🇨🇦Levis, Canada
DIEX Research Quebec Inc.
🇨🇦Quebec, Canada
Alpha Recherche Clinique Inc
🇨🇦Quebec, Canada
Milestone Research Inc.
🇨🇦London, Canada
Yang Medicine
🇨🇦Ottawa, Canada
Clinique de Lebourgneuf
🇨🇦Quebec, Canada
Clinique spécialisée en allergie - Allergy/Immunology/Asthma/Mpoc
🇨🇦Quebec, Canada
Diex Research Sherbrooke Inc
🇨🇦Quebec, Canada
Central Alberta Research Clinic
🇨🇦Red Deer, Canada
Diex Recherche - Joilette - HyperCore - PPDS
🇨🇦Saint-Charles-Borromée, Canada
Glencar Medical Inc.
🇨🇦Sarnia, Canada
Canadian Phase Onward Inc.
🇨🇦Toronto, Canada
Manna Research
🇨🇦Toronto, Canada
LMC
🇨🇦Toronto, Canada
Medicine Professional Corporation
🇨🇦Toronto, Canada
Diex Recherche Victoriaville
🇨🇦Victoriaville, Canada
Diex Recherche Trois-Rivières
🇨🇦Trois-Rivieres, Canada
Colchester East Hants Health Authority - Colchester Regional
🇨🇦Truro, Canada
Sjællands UniHosp, Roskilde - Medicine and Infectious Diseases
🇩🇰Roskilde, Denmark
Aarhus Universitetshospital
🇩🇰Århus N, Denmark
Clinical Research Center
🇪🇪Tartu, Estonia
Center for Clinical and Basic Research
🇪🇪Tallinn, Estonia
Innomedica OÜ
🇪🇪Tallinn, Estonia
Klinische Forschung Berlin-Mitte GmbH
🇩🇪Berlin, Germany
Berliner Centrum für Reise- und Tropenmedizin
🇩🇪Berlin, Germany
Klinische Forschung Berlin
🇩🇪Berlin, Germany
Emovis GmbH
🇩🇪Berlin, Germany
Studienzentrum Dr. Keller
🇩🇪Frankfurt/Main, Germany
Klinische Forschung Dresden GmbH
🇩🇪Dresden, Germany
Medizentrum Essen Borbeck
🇩🇪Essen, Germany
IKF Pneumologie
🇩🇪Frankfurt, Germany
Infektiologikum Frankfurt-Sachsenhausen
🇩🇪Frankfurt, Germany
Synexus Clinical Research GmbH
🇩🇪Leipzig, Germany
Clinical Research Hamburg GmbH
🇩🇪Hamburg, Germany
Siteworks GmbH
🇩🇪Heidelberg, Germany
Klinische Forschung Hamburg GmbH
🇩🇪Hamburg, Germany
Klinische Forschung Hannover-Mitte GmbH
🇩🇪Hannover, Germany
Studienzentrum Brinkum
🇩🇪Wardenburg, Germany
University Hospital Cologne AöR
🇩🇪Köln, Germany
Praxis Illies
🇩🇪Magdeburg, Germany
Dermatologie Quist
🇩🇪Mainz, Germany
Praxis Schaum
🇩🇪Oldenburg, Germany
Hautarztpraxis Leitz & Kollegen
🇩🇪Stuttgart, Germany
Leids Universitair Medisch Centrum (LUMC)
🇳🇱Leiden, Netherlands
Universitair Medisch Centrum (UMC) Utrecht - Julius Center for Health Sciences and Primary Care
🇳🇱Utrecht, Netherlands
Klinische Forschung Schwerin GmbH
🇩🇪Schwerin, Germany
Centrum Medyczne Pratia Bydgoszcz
🇵🇱Bydgoszcz, Poland
Centrum Medyczne AMED Oddzial w Lodzi
🇵🇱Lodz, Poland
Centrum Medyczne Plejady
🇵🇱Krakow, Poland
Krakowskie Centrum Medyczne Sp. z o.o.
🇵🇱Kraków, Poland
ETG Lublin
🇵🇱Lublin, Poland
KO-MED Centra Kliniczne Sp. z o.o.
🇵🇱Zamosc, Poland
Hospital de Antequera
🇪🇸Antequera, Spain
ETG Zamosc
🇵🇱Zamosc, Poland
Hospital Clinic De Barcelona
🇪🇸Barcelona, Spain
Hospital Santa Creu i Sant Pau - Research institut
🇪🇸Barcelona, Spain
Universitat Autonoma de Barcelona (UAB) - Institut d'Investigacio en Atencio Primaria Jordi Gol (IDIAP Jordi Gol)
🇪🇸Barcelona, Spain
Hospital Alvaro Cunqueiro
🇪🇸Vigo, Spain
Hospital Povisa
🇪🇸Vigo, Spain
National Cheng Kung University hospital
🇨🇳Tainan, Taiwan
Kaohsiung Veterans General Hospital
🇨🇳Kaohsiung City, Taiwan
China Medical University Hospital - division of Rheumatology - Taichung
🇨🇳Taichung, Taiwan
National Taiwan University Hospital - Family Medicine
🇨🇳Taipei, Taiwan
Taipei Medical University - WanFang Hospital
🇨🇳Taipei, Taiwan
Royal United Hospital
🇬🇧Bath, United Kingdom
Layton Medical Centre
🇬🇧Blackpool, United Kingdom
University Hospitals of Leicester-Leicester Royal Hospital
🇬🇧Leicester, United Kingdom
GST NHS Found
🇬🇧London, United Kingdom
Panthera Biopartners - Sheffield - multispeciality
🇬🇧Rochdale, United Kingdom
Newcastle University - Institute of Cellular Medicine (ICM)
🇬🇧Newcastle, United Kingdom
Southampton General Hospital
🇬🇧Southampton, United Kingdom
Citrus Cardiology Consultants
🇺🇸Inverness, Florida, United States
Innovation Medical Research Center,inc
🇺🇸Palmetto Bay, Florida, United States
Meridian Clinical Research - Dakota Dunes
🇺🇸Sioux City, Iowa, United States
Paul G Matherne MD
🇺🇸Biloxi, Mississippi, United States
Panthera Biopartners - Manchester - multispeciality
🇬🇧Rochdale, United Kingdom
Panthera Biopartners - Preston - multispeciality
🇬🇧Salford, United Kingdom
Royal Cornwall Hospitals Trust - Respiratory
🇬🇧Truro, United Kingdom
Wake Forest Baptist Medical Center
🇺🇸Winston-Salem, North Carolina, United States
Velocity Clinical Research, Gaffney
🇺🇸Gaffney, South Carolina, United States
Liverpool University Hospitals NHS Foundation Trust - Aintree University Hospital (Fazakerley Hospital)
🇬🇧Liverpool, United Kingdom
Lenzmeier Family Medicine
🇺🇸Glendale, Arizona, United States
North Alabama Research Center, LLC
🇺🇸Athens, Alabama, United States
Fiel Family and Sports Medicine/CCT Research
🇺🇸Tempe, Arizona, United States
Noble Clinical Research
🇺🇸Tucson, Arizona, United States
Velocity Clinical Research, Banning
🇺🇸Banning, California, United States
Lynn Institute of the Ozarks
🇺🇸Little Rock, Arkansas, United States
Baptist Health Center for Clinical Research
🇺🇸Little Rock, Arkansas, United States
Marvel Clinical Research
🇺🇸Huntington Beach, California, United States
Hope Clinical Research, LLC
🇺🇸Canoga Park, California, United States
Velocity Clinical Research, Chula Vista
🇺🇸La Mesa, California, United States
Velocity Clinical Research, San Diego
🇺🇸La Mesa, California, United States
Artemis Institute for Clinical Research
🇺🇸San Diego, California, United States
Empire Clinical Research
🇺🇸Pomona, California, United States
Benchmark Research-Texas
🇺🇸Riverside, California, United States
Hamilton Medical Research Group
🇨🇦Hamilton, Canada
Women's Health Care Research Corp.
🇺🇸San Diego, California, United States
Peninsula Research Associates (PRA)
🇺🇸Rolling Hills Estates, California, United States
Clinical Research Atlanta
🇺🇸Stockbridge, Georgia, United States
Southeast Regional Research Group
🇺🇸Columbus, Georgia, United States
Great Lakes Clinical Trials LLC
🇺🇸Gurnee, Illinois, United States
Medpharmics, LLC
🇺🇸Metairie, Louisiana, United States
Be Well Clinical Studies, LLC
🇺🇸Lincoln, Nebraska, United States
DELRICHT RESEARCH at GULFPORT MEMORIAL
🇺🇸Gulfport, Mississippi, United States
Tryon Medical Group
🇺🇸Charlotte, North Carolina, United States
Sundance Clinical Research, LLC
🇺🇸Saint Louis, Missouri, United States
Velocity Clinical Research - Grants Pass
🇺🇸Grants Pass, Oregon, United States
Velocity Clinical Resarch - Medford
🇺🇸Medford, Oregon, United States
Velocity Clinical Research - Providence
🇺🇸Warwick, Rhode Island, United States
Velocity Clinical Research, Greenville
🇺🇸Anderson, South Carolina, United States
Epic Medical Research, LLC
🇺🇸Red Oak, Texas, United States
Velocity Clinical Research - Salt Lake City
🇺🇸West Jordan, Utah, United States
Toronto Western Hospital
🇨🇦Toronto, Canada
Odense University Hospital
🇩🇰Odense, Denmark
Merelahe Family Doctors Centre
🇪🇪Tallinn, Estonia
Hull University Teaching Hospitals NHS Foundation trust
🇬🇧Hull, United Kingdom
Nathan H Fischman MD LLC
🇺🇸New Orleans, Louisiana, United States
Clinical Research Partners, LLC
🇺🇸Richmond, Virginia, United States
Velocity Clinical Research - Greenville
🇺🇸Greenville, South Carolina, United States
Radiant Research
🇺🇸Akron, Ohio, United States